NEW YORK, April 27 – Exelixis and AVI BioPharma have agreed to partner in a drug development alliance using Exelixis’ zebrafish functional genomics technologies and AVI’s antisense agents, the companies said Friday.
Already have a GenomeWeb or 360Dx account?Login Now.
In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.
Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.
The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.
In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.